Pediococcus acidilactici LTJ51 with lipid-lowering and weight-losing capacity as well as metagen and application of pediococcus acidilactici LTJ51
Through the application of LTJ51 and its epibiotic, the weight rebound and side effects caused by existing weight loss products and drugs have been solved, effectively reducing lipids and improving blood lipids, and providing a safe obesity treatment plan.
Patent Information
- Application Number
- CN202411353572.8
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-09-26
- Publication Date
- 2024-12-17
AI Technical Summary
Existing weight loss products and drugs may cause weight rebound in the short term, and are often accompanied by damage to the intestinal microenvironment and serious side effects, which cannot effectively solve the problem of obesity in the long run.
Using a microorganism called LTJ51, the epibiotics are prepared by preparing their epibiotics, and the dead cells and bacterial lysates are prepared by heat treatment and drying technology to form high temperature and gastric acid-resistant products to reduce total cholesterol and glycerol. Ester levels prevent fat cell enlargement induced by high-fat diet.
Effectively inhibit weight growth, reduce blood lipid levels, extend product shelf life, enhance body function, and provide safe lipid-reducing and weight loss solutions suitable for health care products and medicines.
Smart Images
Figure CN119144498A_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the technical field of microorganisms and postbiotics, in particular to a strain of Pediococcus acidilactici LTJ51 with lipid-lowering and weight-loss capabilities, a postbiotic and an application thereof. Background Art
[0002] Probiotics are a type of active microorganisms that are beneficial to the host by colonizing in the human body and changing the composition of the host's flora in a certain part. They promote nutrient absorption and maintain intestinal health by regulating the host's mucosal and systemic immune functions or by regulating the balance of intestinal flora, thereby producing single microorganisms or mixed microorganisms with clear composition that are beneficial to health. Lactic acid bacteria, as the main species of probiotics, participate in the role of human intestinal microorganisms, and their metabolites, such as acetic acid, play an important role in host health.
[0003] Pediococcus acidilactici is a type of lactic acid bacteria. Its cells are spherical and divide alternately at right angles to form a tetrad. Generally, cells grow in pairs, solitary cells are rare, and they are not arranged in chains. It is Gram-positive, non-motile, and facultatively anaerobic. The colonies on MRS medium are small and white. It produces acid, regulates gastrointestinal flora, and maintains the balance of intestinal microecology. It has an antagonistic effect on pathogenic microorganisms in animals, can competitively inhibit pathogenic microorganisms, enhance the immune function of the animal body, produce beneficial metabolites, activate the activity of acid proteases, participate in the body's metabolism, and prevent the production of harmful substances. As the main probiotic group in the human gastrointestinal tract, Pediococcus acidilactici has multiple functions such as maintaining the balance of intestinal flora, improving the body's immunity, and promoting the absorption of nutrients. Pediococcus acidilactici is widely used in the food industry.
[0004] Postbiotics are preparations of inanimate microorganisms and their components that are beneficial to the health of the host after probiotics are processed, including bacteria and their metabolites. Compared with traditional probiotics, postbiotics are resistant to high temperatures, stomach acid, and choline, have unlimited post-processing capabilities, extend product shelf life, and are easy to transport and package. Some postbiotics that have been screened and tested are better than original live bacteria in enhancing the body's immune ability. Even after entering the human body and being processed by gastrointestinal digestive juices, they still retain a high degree of physiological activity.
[0005] Obesity is a chronic disease caused by excessive accumulation of body fat due to the interaction of genetics, environment and endocrine factors. Obesity not only affects appearance, but also causes many serious harms to the body, such as shortened life expectancy, high blood pressure, heart disease, cerebrovascular disease, diabetes, fatty liver, snoring, tumors and osteoarthritis, etc., posing a threat to human health.
[0006] Common weight loss products include detoxification tea, slimming tea, L-carnitine, sibutramine, metformin, etc. Detoxification tea and slimming tea, these weight loss health products can only reduce weight in the short term, are very easy to rebound, and easily damage the intestinal microenvironment, leading to other side effects. And some weight loss drugs such as sibutramine, doctors have found that this drug can cause stroke, arrhythmia, and uncontrollable hypertension, so all sold drugs can only be recalled. The side effects it brings to the body are usually unacceptable. "Diet pills can have relatively serious side effects on the human body. Usually most diet pills will irritate the intestines and gastrointestinal tract of the human body, resulting in a decrease in appetite. In severe cases, there will even be symptoms of anorexia. In addition, most patients will experience gastrointestinal reactions after taking weight loss drugs, such as nausea, vomiting, abdominal pain, diarrhea and other symptoms, and may even induce headaches, insomnia, endocrine disorders and other symptoms.
[0007] Therefore, there is an urgent need for one or several related new probiotics, products, drugs, etc. Summary of the invention
[0008] The purpose of the present invention is to overcome the shortcomings of the prior art and provide a strain of Pediococcus acidilactici LTJ51 with lipid-lowering and weight-loss capabilities, as well as postbiotics and applications thereof.
[0009] The technical solution adopted by the present invention to solve its technical problem is:
[0010] A strain of Pediococcus acidilactici LTJ51 with the ability to lower blood lipids and lose weight, the name of the Pediococcus acidilactici is: LTJ51, the classification name is: Pediococcus acidilactici, the preservation number is: CGMCC No.31545, the preservation date is: August 5, 2024, the preservation unit is: General Microbiology Center of China Microbiological Culture Collection Administration, No. 3, Yard 1, Beichen West Road, Chaoyang District, Beijing.
[0011] Furthermore, the colony and bacterial characteristics of the strain are as follows: after culturing on MRS medium for 24 hours, the colonies are white, opaque, protruding, moist, with smooth edges and glossy, with a colony diameter of 0.8 to 1.0 mm, and the cell morphology is observed under an optical microscope, and Gram staining is G + , the bacteria are short rod-shaped;
[0012] The lactic acid Pediococcus LTJ51 is a Gram-positive bacterium that does not form spores and is facultatively anaerobic. Its optimum growth temperature is 30-35° C. and its optimum growth pH is 6.0-7.0.
[0013] Alternatively, the strain is isolated from white wine mash, and the source is safe.
[0014] A Pediococcus acidilactici postbiotic prepared by using the Pediococcus acidilactici LTJ51 as described above.
[0015] Furthermore, the preparation method of the postbiotics is to inoculate the Pediococcus acidilactici LTJ51 into a fermentation medium to obtain a fermentation liquid, perform heat treatment at 80-100° C. for 25-35 minutes and perform cracking to obtain the postbiotics.
[0016] Furthermore, the postbiotics include dead cells, bacterial lysates, and bacterial fermentation broth;
[0017] Alternatively, the postbiotics can be processed into powder by various drying methods such as vacuum drying, spray drying, vacuum freeze drying, fluidized bed drying, etc., or used directly or dissolved in physiological saline for use.
[0018] Furthermore, the dead cells are obtained by centrifuging the fermented bacterial solution at 4000 rpm / min to obtain a bacterial sludge precipitate, washing with physiological saline, dissolving in physiological saline, and heat-treating to obtain an inactivated bacterial cell solution;
[0019] Alternatively, the preparation method of the bacterial lysate is: inoculating the lactic acid Pediococcus acidilactici LTJ51 into a fermentation medium to obtain a fermentation liquid, heat-treating the fermentation liquid at 80-100° C. for 25-35 minutes, high-pressure homogenizing the heat-treated fermentation liquid, and centrifuging to obtain a bacterial lysate.
[0020] Furthermore, compared with live bacteria, the lactic acid Pediococcus postbiotics are resistant to high temperatures, stomach acid, and choline, have unlimited post-processing capabilities, extend product shelf life, and are easy to transport and package;
[0021] Alternatively, the Pediococcus acidilactici postbiotics all improved the weight gain of obese mice;
[0022] The Pediococcus acidilactici postbiotic can reduce the levels of total cholesterol and triglycerides and prevent the enlargement of fat cells induced by a high-fat diet.
[0023] Use of the above-mentioned Pediococcus acidilactici postbiotics in the preparation of health products and / or medicines for relieving and / or treating lipid-lowering and weight-loss;
[0024] Alternatively, use in the preparation of a microbial preparation for producing short-chain fatty acids.
[0025] Use of the above-mentioned Pediococcus acidilactici LTJ51 in the preparation of health products and / or medicines for relieving and / or treating lipid-lowering and weight-loss;
[0026] Alternatively, use in the preparation of a microbial preparation for producing short-chain fatty acids.
[0027] The advantages and positive effects achieved by the present invention are:
[0028] 1. The Pediococcus acidilactici of the present invention is derived from the fermented grains in the fermentation process of the traditional fermented food liquor, and is a recognized safe strain of bacteria that can be used for food. The source of Pediococcus acidilactici LTJ51 is safe and non-pathogenic. The Pediococcus acidilactici of the present invention has the effect of alleviating, improving or treating HFD-induced obesity.
[0029] 2. The postbiotics prepared by Pediococcus acidilactici of the present invention have the advantages of high temperature resistance, gastric acid resistance, choline resistance, extended product shelf life, easy transportation and packaging, and can be widely used in health foods and medicines.
[0030] 3. The Pediococcus acidilactici of the present invention is derived from the fermented grains in the fermentation process of the traditional fermented food liquor, and is a recognized safe strain that can be used for food. The Pediococcus acidilactici LTJ51 provided by the present invention and the postbiotics prepared therefrom have the effect of alleviating, improving or treating HFD-induced obesity, can effectively inhibit the growth of body weight, reduce the levels of total cholesterol and triglycerides, and prevent the enlargement of fat cells induced by a high-fat diet, thereby alleviating, improving or treating HFD-induced obesity and enhancing body function.
[0031] 4. The Pediococcus acidilactici LTJ51 of the present invention can be used in the preparation of health products or medicines for alleviating, improving or treating HFD-induced obesity.
[0032] The Pediococcus acidilactici LTJ51 of the present invention plays the role of alleviating or treating obesity by inhibiting weight gain and improving blood lipid levels.
[0033] The Pediococcus acidilactici LTJ51 of the present invention can be used in the preparation of a microbial preparation for producing short-chain fatty acids. BRIEF DESCRIPTION OF THE DRAWINGS
[0034] Figure 1 The colony morphology (left picture) and cell morphology (right picture) of Pediococcus acidilactici CGMCC No.31545 in the present invention are shown;
[0035] Figure 2 16S rDNA phylogenetic tree diagram of Pediococcus acidilactici CGMCC No.31545 in the present invention;
[0036] Figure 3 This is a comparison chart of the weight changes of mice in each group at 10 weeks in the present invention;
[0037] Figure 4 This is a comparison chart of the weight gain of mice in each group at 10 weeks in the present invention;
[0038] Figure 5 It is a graph showing the four blood lipid levels of Pediococcus acidilactici CGMCC No.31545 and its postbiotics after intervention in the present invention;
[0039] Figure 6 This is a comparison of HE staining of epididymal adipose tissue in each group after intervention with Pediococcus acidilactici CGMCC No.31545 and its postbiotics in the present invention.
[0040] A strain of Pediococcus acidilactici LTJ51 with the ability to lower blood lipids and lose weight, the name of the Pediococcus acidilactici is: LTJ51, the classification name is: Pediococcus acidilactici, the preservation number is: CGMCC No.31545, the preservation date is: August 5, 2024, the preservation unit is: General Microbiology Center of China Microbiological Culture Collection Administration, No. 3, Yard 1, Beichen West Road, Chaoyang District, Beijing. DETAILED DESCRIPTION
[0041] The present invention will be further described below in conjunction with the embodiments. The following embodiments are descriptive rather than restrictive, and the protection scope of the present invention cannot be limited by the following embodiments.
[0042] The various experimental operations involved in the specific embodiments are all routine techniques in the art. For parts not specially annotated in this document, ordinary technicians in the art can implement them by referring to various commonly used reference books, scientific and technological literature or related instructions, manuals, etc. before the filing date of this invention.
[0043] A strain of Pediococcus acidilactici LTJ51 with the ability to lower blood lipids and lose weight, the name of the Pediococcus acidilactici is: LTJ51, the classification name is: Pediococcus acidilactici, the preservation number is: CGMCC No.31545, the preservation date is: August 5, 2024, the preservation unit is: General Microbiology Center of China Microbiological Culture Collection Administration, No. 3, Yard 1, Beichen West Road, Chaoyang District, Beijing.
[0044] Preferably, the colony and bacterial characteristics of the strain are: Figure 1 As shown, after culturing on MRS medium for 24 hours, the colonies were small, white, opaque, protruding, moist, with smooth edges and glossy, with a colony diameter of 0.8-1.0 mm. Its cell morphology was observed under an optical microscope, and Gram staining showed G + , the bacteria are spherical;
[0045] The lactic acid Pediococcus LTJ51 is a Gram-positive bacterium that does not form spores and is facultatively anaerobic. Its optimum growth temperature is 30-35° C. and its optimum growth pH is 6.0-7.0.
[0046] Alternatively, the strain is isolated from white wine mash, and the source is safe.
[0047] A Pediococcus acidilactici postbiotic prepared by using the Pediococcus acidilactici LTJ51 as described above.
[0048] Preferably, the preparation method of the postbiotics is to inoculate the Pediococcus acidilactici LTJ51 into a fermentation medium to obtain a fermentation liquid, perform heat treatment at 80-100° C. for 25-35 min and perform cracking to obtain the postbiotics.
[0049] Preferably, the postbiotics include dead cells, bacterial lysates, and bacterial fermentation broth;
[0050] Alternatively, the postbiotics can be processed into powder by various drying methods such as vacuum drying, spray drying, vacuum freeze drying, fluidized bed drying, etc., or used directly or dissolved in physiological saline for use.
[0051] Preferably, the dead cells are obtained by centrifuging the fermented bacterial liquid at 4000 rpm / min to obtain a bacterial sludge precipitate, washing it with physiological saline, dissolving it in physiological saline, and heat-treating it to obtain an inactivated bacterial cell solution;
[0052] Alternatively, the preparation method of the bacterial lysate is: inoculating the lactic acid Pediococcus acidilactici LTJ51 into a fermentation medium to obtain a fermentation liquid, heat-treating the fermentation liquid at 80-100° C. for 25-35 minutes, high-pressure homogenizing the heat-treated fermentation liquid, and centrifuging to obtain a bacterial lysate.
[0053] Preferably, the lactic acid Pediococcus postbiotics are resistant to high temperatures, stomach acid, and choline compared to live bacteria, have unlimited post-processing capabilities, extend product shelf life, and are easy to transport and package;
[0054] Alternatively, the Pediococcus acidilactici postbiotics all improved the weight gain of obese mice;
[0055] The Pediococcus acidilactici postbiotic can reduce the levels of total cholesterol and triglycerides and prevent the enlargement of fat cells induced by a high-fat diet.
[0056] Use of the above-mentioned Pediococcus acidilactici postbiotics in the preparation of health products and / or medicines for relieving and / or treating lipid-lowering and weight-loss;
[0057] Alternatively, use in the preparation of a microbial preparation for producing short-chain fatty acids.
[0058] Use of the above-mentioned Pediococcus acidilactici LTJ51 in the preparation of health products and / or medicines for relieving and / or treating lipid-lowering and weight-loss;
[0059] Alternatively, use in the preparation of a microbial preparation for producing short-chain fatty acids.
[0060] Preferably, mice gavaged with the Pediococcus acidilactici LTJ51 strain and its heat-killed postbiotics gain less weight than HFD-induced obese mice.
[0061] The strain of Pediococcus acidilactici as described above has the effect of alleviating and improving obesity.
[0062] The postbiotics prepared by heat-inactivating a strain of Pediococcus acidilactici as described above have the effect of alleviating, improving or treating HFD-induced obesity.
[0063] Specifically, the following examples illustrate the technical solutions of the present invention from the perspectives of isolation and identification of strains, etc. The specific contents are as follows.
[0064] Example 1 Isolation and Identification of Lactic Acid Bacteria
[0065] The following experiments were performed under sterile conditions.
[0066] 1. Enrichment of strains
[0067] Weigh 25 g of fermented grains from the fermentation process of liquor (derived from the fermented grains of the traditional fermented food liquor fermentation process of Lutaichun in Tianjin, China), add 225 mL of sterile saline and mix well. Dilute the obtained bacterial solution by 10 3 ~10 5 After doubling, 100 μL was spread on an MRS plate, inverted and cultured at 37°C for 24 h, and the growth of the colonies was observed.
[0068] The preparation method of the MRS solid culture medium is as follows: 10g of peptone, 5g of beef extract powder, 1mL of Tween 80, 2g of dipotassium hydrogen phosphate, 4g of yeast extract powder, 0.2g of magnesium sulfate, 2g of ammonium citrate, 20g of glucose, 0.05g of manganese sulfate, 5g of sodium acetate, 20g of agar, 1L of distilled water, pH 6.2±0.2, sterilized at 121°C for 20min for use.
[0069] 2. Isolation of strains
[0070] Pick the colonies obtained in step 1, examine them under a microscope using Gram staining, observe the morphological characteristics of the bacteria, and select Gram-positive bacteria as the target strains. Figure 1 As shown, the cell morphology was observed under an optical microscope, and Gram staining showed G + , the bacteria are spherical.
[0071] 3. Purification of strains
[0072] Pick the colonies obtained in step 2 and streak them on the MRS plate. Repeat the purification until there are no other bacteria. Record the status of different colonies. Figure 1 As shown, after culturing on MRS medium for 24 hours, the colonies were small, white, opaque, raised, moist, with smooth edges and glossy appearance.
[0073] 4. Identification of strains
[0074] The bacterial genomic DNA rapid extraction kit was used to extract the genome of the lactic acid bacteria strain, and PCR amplification was performed using this as a template. The successfully amplified PCR products were sequenced and spliced to obtain the DNA sequence, and the sequence homology was compared and analyzed using the BLAST search system of NCBI. The known strain with the highest similarity was selected and its similarity was analyzed. The neighbor-joining method (NJ) in the MEGA5 software was used to establish a phylogenetic tree. The phylogenetic tree is shown in Figure 2 shown.
[0075] The pure bacteria obtained in step 3 were subjected to physiological and biochemical experimental studies. The strain was cultured on MRS medium for 24 hours, and the colonies were white, opaque, protruding, moist, with smooth edges and glossy, with a colony diameter of 0.8-1.0 mm. Its cell morphology was observed under an optical microscope, and Gram staining showed G + The bacteria are in the shape of small short rods.
[0076] By homology comparison using BLAST software, combined with colony morphological characteristics, cell morphological characteristics and 16S rDNA gene sequence results, it was determined to be a new strain of Pediococcus acidilactici in the genus Pediococcus. The strain was deposited in the General Microbiology Center of China Microorganism Culture Collection (CGMCC) on August 5, 2024, with the deposit number CGMCC No.31545, and the address is: No. 3, Yard 1, Beichen West Road, Chaoyang District, Beijing.
[0077] Example 2 Preparation of postbiotics by Pediococcus acidilactici LTJ51
[0078] The solid MRS culture medium was cultured in a water-insulated constant temperature incubator at 37°C for 24-48 hours to obtain a single colony; the single colony was picked and inoculated into an MRS liquid culture medium, and cultured at 37°C for 12-16 hours to obtain a culture solution 1; the culture solution 1 was inoculated into an MRS liquid culture medium at an inoculation rate of 2% (v / v, volume ratio), and cultured at 37°C for 12 hours to obtain a seed solution; the seed solution was inoculated into an MRS liquid culture medium at a rate of 3-5% (v / v, volume ratio) for expansion culture, and cultured at 37°C for 18-24 hours to obtain a concentration of 8.1×10 9 CFU / ml of bacterial solution.
[0079] The bacterial liquid was centrifuged at 4000 rpm to obtain bacterial sludge, which was washed three times with physiological saline. The finally obtained bacterial sludge was dissolved in physiological saline (mass fraction 0.9%) and heat-treated at 100° C. for 30 min to obtain heat-killed Pediococcus acidilactici LTJ51 postbiotics.
[0080] The preparation method of the MRS liquid culture medium is as follows: 10g of peptone, 5g of beef extract powder, 1mL of Tween 80, 2g of dipotassium hydrogen phosphate, 4g of yeast extract powder, 0.2g of magnesium sulfate, 2g of ammonium citrate, 20g of glucose, 0.05g of manganese sulfate, 5g of sodium acetate, 1L of distilled water, pH 6.2±0.2, sterilized at 121°C for 20min for use.
[0081] Example 3 Effect of Pediococcus acidilactici LTJ51 on HFD-induced obese mouse model
[0082] 1. Establishment of mouse experimental model
[0083] 50 mice were divided into a blank control group (Normal Control) of 10, a model control group (Model) of 10, a probiotic group (LTJ51) of 10 lactic acid Pediococcus acidilactici LTJ51 (LTJ51), a postbiotic group (LTJ51PB, the preparation method of the postbiotics used is the same as in Example 2) of 10, and an orlistat positive control group (OLYM) of 10 according to a random number table. All mice were free to eat and drink water. The mice were weighed once every two days as the basis for dosing, and the medication was administered for a total of 8 weeks. The specific dosing regimen is shown in Table 1. Among them, the lactic acid Pediococcus acidilactici LTJ51 prepared in Example 1 was centrifuged to obtain a bacterial sludge, which was diluted with physiological saline (mass fraction 0.9%) to a bacterial content of not less than 1×10 7 CFU / mL of bacterial solution.
[0084] After 10 weeks of oral drug intervention, Figure 3As shown, the probiotics of lactic acid Pediococcus LTJ51 and its postbiotics all showed different degrees of reduction effect on the weight gain of high-fat obese mice and were lower than the model group (Model). Among them, the LTJ51 group had the most significant effect on reducing the weight gain of high-fat obese mice, with a weight growth rate of 45.6% (basic group 36.5%, high-fat diet group 67.7%). During the first four weeks of feeding, the effect of reducing weight gain in the drug-treated group was not obvious. As the intervention time became longer, it began to show a significant inhibitory effect on weight gain.
[0085] The weight index of animal experiments showed that the probiotics Pediococcus acidilactici LTJ51 and its postbiotics have the effect of reducing fat and weight. The fat reduction effect of the LTJ51 group is the most obvious.
[0086] like Figure 4 As shown, the weight growth rate of the treatment groups was significantly lower than that of the model group, among which the LTJ51 group was almost the same as the blank control group, and the effect of the LTJ51 group was slightly better than that of the LTJ51PB group.
[0087] Table 1 Dosage regimen
[0088]
[0089]
[0090] 2. Four blood lipid test items: TC, TG, LDL-C, HDL-C
[0091] The mice were killed after 10 weeks of modeling, and the mouse serum was collected to measure the four blood lipids in the serum of each group of mice, including total cholesterol (TC), triglycerides (TG), low-density lipoprotein cholesterol (LDL-C), and high-density lipoprotein cholesterol (HDL-C). The changes in blood lipid levels were used to determine the effects of Pediococcus acidilactici LTJ51 and its postbiotics on improving HFD-induced high-fat obesity. Figure 5 It can be seen that the TC level of the model group was about 4.2mmol / L, which was significantly higher than 2.3mmol / L in the normal group, and the LTJ51, LTJ51PB, and OLYM groups were significantly lower than the model group; the TG level of the model group was 1.0mmol / L, which was about 1.6 times higher than that of the normal group, and the LTJ51, LTJ51PB, and OLYM groups were significantly lower than the model group; the LDL-C and HDL-C levels of the model group were not significantly different from those of the model group. This shows that the lactic acid Pediococcus LTJ51 group and its postbiotic group have improved HFD-induced obesity.
[0092] 3. HE staining experiment of epididymal adipose tissue
[0093] The mice were killed after 10 weeks of modeling, and epididymal fat was taken from the mice. The fat of mice in each group was stained with HE and observed. The results are shown in Figure 6 The fat cells of the model group mice were significantly larger than those of the normal group. The fat cells of the normal group were closely arranged and uniform in size. The fat cells of the LTJ51, LTJ51PB, and OLYM groups in the intervention treatment groups were significantly smaller than those of the model group, and most of them were relatively uniform in size. Each treatment group was able to prevent the enlargement of fat cells induced by a high-fat diet to varying degrees. This shows that Pediococcus acidilactici LTJ51 and its postbiotics can improve or inhibit obesity in mice.
[0094] Although the embodiments of the present invention are disclosed for illustrative purposes, those skilled in the art will appreciate that various substitutions, changes and modifications are possible without departing from the spirit and scope of the present invention and the appended claims. Therefore, the scope of the present invention is not limited to the contents disclosed in the embodiments.
Claims
1. A strain of Pediococcus acidilactici LTJ51 having lipid-lowering and weight-loss abilities, characterized in that: The name of the Pediococcus acidilactici is: LTJ51, the classification name is: Pediococcus acidilactici, the preservation number is: CGMCC No.31545, the preservation date is: August 5, 2024, and the preservation unit is: General Microbiology Center of China Microbiological Culture Collection Administration, No. 3, Yard No. 1, Beichen West Road, Chaoyang District, Beijing.
2. The Pediococcus acidilactici LTJ51 having lipid-lowering and weight-loss ability according to claim 1, characterized in that: The colony and bacterial characteristics of the strain are as follows: after culturing on MRS medium for 24 hours, the colonies are white, opaque, protruding, moist, with smooth edges and gloss, with a colony diameter of 0.8 to 1.0 mm, and the cell morphology is observed under an optical microscope, and Gram staining is G + , the bacteria are short rod-shaped; The Pediococcus acidilactici LTJ51 is a Gram-positive bacterium that does not produce spores and is facultatively anaerobic. Its optimum growth temperature is 30-35° C. and its optimum growth pH is 6.0-7.
0. Alternatively, the strain is isolated from white wine mash, and the source is safe.
3. A Pediococcus acidilactici postbiotic prepared using the Pediococcus acidilactici LTJ51 as claimed in claim 1 or 2.
4. The Pediococcus acidilactici postbiotic according to claim 3, characterized in that: The preparation method of the postbiotics comprises the following steps: inoculating the Pediococcus acidilactici LTJ51 into a fermentation medium to obtain a fermentation liquid, performing heat treatment at 80 to 100° C. for 25 to 35 minutes and performing lysis to obtain the postbiotics.
5. The Pediococcus acidilactici postbiotic according to claim 3, characterized in that: The postbiotics include dead cells, bacterial lysates, and bacterial strain fermentation broth; Alternatively, the postbiotics can be processed into powder by a drying method and used directly or dissolved in physiological saline.
6. The Pediococcus acidilactici postbiotic according to claim 5, characterized in that: The dead cells are obtained by centrifuging the fermented bacterial liquid at 4000 rpm / min to obtain a bacterial sludge precipitate, washing it with physiological saline, dissolving it in physiological saline, and heat-treating it to obtain an inactivated bacterial cell solution; Alternatively, the preparation method of the bacterial lysate is: inoculating the Pediococcus acidilactici LTJ51 into a fermentation medium to obtain a fermentation liquid, heat-treating the fermentation liquid at 80-100° C. for 25-35 minutes, high-pressure homogenizing the heat-treated fermentation liquid, and centrifuging to obtain a bacterial lysate.
7. The Pediococcus acidilactici postbiotic according to any one of claims 3 to 6, characterized in that: Compared with live bacteria, the Pediococcus acidilactici postbiotics are resistant to high temperatures, stomach acid, and choline, have unlimited post-processing capabilities, extend product shelf life, and are easy to transport and package; Alternatively, the Pediococcus acidilactici postbiotics improve the weight gain of obese mice; The Pediococcus acidilactici postbiotic can reduce the levels of total cholesterol and triglycerides and prevent the enlargement of fat cells induced by a high-fat diet.
8. Use of the Pediococcus acidilactici postbiotic according to any one of claims 3 to 7 in the preparation of health products and / or medicines for relieving and / or treating lipid-lowering and weight-loss; Alternatively, use in the preparation of a microbial preparation for producing short-chain fatty acids.
9. Use of Pediococcus acidilactici LTJ51 as claimed in claim 1 or 2 in the preparation of health products and / or medicines for relieving and / or treating lipid-lowering and weight-loss; Alternatively, use in the preparation of a microbial preparation for producing short-chain fatty acids.